Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription Articles published in PLoS Med Retrieve available abstracts of 14 articles: HTML format

Single Articles

June 2025
1. SHEN J, Kharitonova E, Tytula A, Zawieja J, et al
   Vaccination strategies, public health impact and cost-effectiveness of dengue vaccine TAK-003: A modeling case study in Thailand.
   PLoS Med. 2025;22:e1004631.
   PubMed     Abstract available
   
   
   April 2025
2. 
   Correction: Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
   PLoS Med. 2025;22:e1004605.
   PubMed     Abstract available
   
   
   February 2025
3. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
   Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
   PLoS Med. 2025;22:e1004521.
   PubMed     Abstract available
   
   
   
4. INGABIRE R, Nyombayire J, Mazzei A, Mazarati JB, et al
   Contraception use and pregnancy in women receiving a 2-dose Ebola vaccine in Rwanda: A retrospective analysis of UMURINZI vaccination campaign data.
   PLoS Med. 2025;22:e1004508.
   PubMed     Abstract available
   
   
   
5. GRAIS RF, Neuzil KM, Rees H, Toscano CM, et al
   Protecting mother and baby: Learnings from an Ebola vaccination campaign on the evolving landscape of vaccines and pregnancy.
   PLoS Med. 2025;22:e1004530.
   PubMed     Abstract available
   
   
   
6. GUTTIERES D, Diepvens C, Grais RF, Kiarie J, et al
   Charting a novel path towards Ebola virus disease preparedness: Considerations for preventive vaccination.
   PLoS Med. 2025;22:e1004543.
   PubMed     Abstract available
   
   
   January 2025
7. SEIDLEIN LV
   Roll out and prospects of the malaria vaccine R21/Matrix-M.
   PLoS Med. 2025;22:e1004515.
   PubMed     Abstract available
   
   
   
8. GENG L, Whittles LK, Dickens BL, Chio MTW, et al
   Correction: Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.
   PLoS Med. 2025;22:e1004573.
   PubMed     Abstract available
   
   
   October 2024
9. MUNDAY JD, Atkins KE, Klinkenberg D, Meurs M, et al
   Estimating the risk and spatial spread of measles in populations with high MMR uptake: Using school-household networks to understand the 2013 to 2014 outbreak in the Netherlands.
   PLoS Med. 2024;21:e1004466.
   PubMed     Abstract available
   
   
   September 2024
10. INIZAN C, Courtot A, Sturmach C, Griffon AF, et al
    Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    PLoS Med. 2024;21:e1004397.
    PubMed     Abstract available
    
    
    June 2024
11. PEREZ CHACON G, Estcourt MJ, Totterdell J, Marsh JA, et al
    Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
    PLoS Med. 2024;21:e1004414.
    PubMed     Abstract available
    
    
    
12. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
    Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
    PLoS Med. 2024;21:e1004375.
    PubMed     Abstract available
    
    
    April 2024
13. JUNG SM, Loo SL, Howerton E, Contamin L, et al
    Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
    PLoS Med. 2024;21:e1004387.
    PubMed     Abstract available
    
    
    March 2024
14. MOODIE Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, et al
    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    PLoS Med. 2024;21:e1004360.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.